id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-303800-h3lvbldz	Schultz, Brittney	Reply to “Treatment considerations for patients with pemphigus during the COVID-19 pandemic”	2020-09-04		.txt	text/plain	483	38	51	title: Reply to "Treatment considerations for patients with pemphigus during the COVID-19 pandemic" In particular, rituximab should be considered 43 for patients with severe disease and without active COVID-19 illness after discussion of specific 44 individual-level risks (age, comorbidities, occupation) and benefits of rituximab. We would also 45 consider rituximab for younger patients without comorbidities and with less severe disease. We have limited data directly 47 comparing adverse events in those treated with rituximab versus other therapies but compared to 48 prednisone alone, individuals treated with rituximab plus short-term prednisone had decreased 49 cumulative exposure to prednisone and fewer adverse effects, 2 including known risk factors for Conversely, physicians should discuss that rituximab may reduce immune response to 63 vaccination, 5 which may decrease the ability of patients to effectively receive a COVID-19 64 vaccine. Treatment considerations for patients 80 with pemphigus during the COVID-19 pandemic	./cache/cord-303800-h3lvbldz.txt	./txt/cord-303800-h3lvbldz.txt